Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

RACECADOTRIL IMPURITY G CRS (15 MG)

RACECADOTRIL IMPURITY G CRS (15 MG)

NA

DISCOVER
TINIDAZOLE IMPURITY A CRS (15MG)

TINIDAZOLE IMPURITY A CRS (15MG)

88054-22-2

DISCOVER
RACECADOTRIL FOR PEAK IDENTIFICATION CRS (5 MG)

RACECADOTRIL FOR PEAK IDENTIFICATION CRS (5 MG)

81110-73-8

DISCOVER
METHYLPHENIDATE IMPURITY MIXTURE CRS (0.04 MG)

METHYLPHENIDATE IMPURITY MIXTURE CRS (0.04 MG)

NA

DISCOVER
PARAFFIN (YELLOW SOFT) CRS (10 MG)

PARAFFIN (YELLOW SOFT) CRS (10 MG)

8002-74-2

DISCOVER
PARAFFIN (WHITE SOFT) CRS (10MG)

PARAFFIN (WHITE SOFT) CRS (10MG)

8002-74-2

DISCOVER
HYPROMELLOSE  PHTHALATE CRS (10 MG)

HYPROMELLOSE PHTHALATE CRS (10 MG)

9050-31-1

DISCOVER
FLUVOXAMINE IMPURITY D CRS (10 MG)

FLUVOXAMINE IMPURITY D CRS (10 MG)

NA

DISCOVER
PANTOPRAZOLE  FOR SYSTEM SUITABILITY CRS (5 MG)

PANTOPRAZOLE FOR SYSTEM SUITABILITY CRS (5 MG)

164579-32-2

DISCOVER
TETRACAINE FOR SYSTEM SUITABILITY CRS (2.04 MG)

TETRACAINE FOR SYSTEM SUITABILITY CRS (2.04 MG)

136-47-0

DISCOVER
TELMISARTAN FOR SYSTEM SUITABILITY CRS (0.26 MG)

TELMISARTAN FOR SYSTEM SUITABILITY CRS (0.26 MG)

144701-48-4

DISCOVER
DYDROGESTERONE CRS (60 MG)

DYDROGESTERONE CRS (60 MG)

152-62-5

DISCOVER